Ramucirumab: EU approval for lung and metastatic colorectal cancer
Ramucirumab: EU approval for lung and metastatic colorectal cancer29 Jan 2016
Lilly’s treatment ramucirumab received approval by the European Commission for two new indications. In particular, ramucirumab will be used as a treatment for advanced non-small cell lung cancer and metastatic colorectal cancer.
Ramucirumab in combination with docetaxel and folfiri
Ramucirumab in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression after platinum-based chemotherapy.
Ramucirumab in combination with FOLFIRI (irinotecan, folinic acid, and 5 fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.
“A significant need for new second-line treatment options”
“Lung and colorectal cancer are the two top leading causes of cancer deaths in the EU and, despite treatment advances, there continues to be a significant need for new second-line treatment options for people with these types of cancer,” said Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology.
“We are pleased to offer ramucirumab as a new option in these treatment settings as we continue delivering on Lilly’s commitment to people living with lung and gastrointestinal cancers.”
Source: eCancer News